Covid-19 has caused multiple disruptions to the clinical trial landscape, extending to studies in all therapy areas, including those in the cardiovascular and metabolic disorder (CVMD) field. Since the beginning of the year, numerous trials postponed their estimated start dates, with some suspended and others postponed indefinitely.

While the futures of a large number of trials affected by the pandemic remain uncertain, some have resumed activity. Read more here.